Amplicon details |
||
Amplicon: |
215 bp | |
1 ctcaccttgc tcctgccgag aaagtatcca tcatggctga tgcaatgcgg 51 cggctgcata cgcttgatcc ggctacctgc ccattcgacc accaagcgaa 101 acatcgcatc gagcgagcac gtactcggat ggaagccggt cttgtcgatc 151 aggatgatct ggacgaagag catcaggggc tcgcgccagc cgaactgttc 201 gccaggctca aggcg |
Record ID | Database | Record description | Record length | Taxon | Method | Amplicon size | Match details |
---|---|---|---|---|---|---|---|
LZ186249.1 | emblrelpat | JP 2017141261-A/12: THERAPEUTIC COM... | 8003 bp | synthetic construct | QL-ELE-00-002 | 215 bp | View |
LZ186250.1 | emblrelpat | JP 2017141261-A/13: THERAPEUTIC COM... | 7916 bp | synthetic construct | QL-ELE-00-002 | 215 bp | View |
LZ186251.1 | emblrelpat | JP 2017141261-A/14: THERAPEUTIC COM... | 7662 bp | synthetic construct | QL-ELE-00-002 | 215 bp | View |
LZ186252.1 | emblrelpat | JP 2017141261-A/15: THERAPEUTIC COM... | 7931 bp | synthetic construct | QL-ELE-00-002 | 215 bp | View |
LZ186253.1 | emblrelpat | JP 2017141261-A/16: THERAPEUTIC COM... | 7931 bp | synthetic construct | QL-ELE-00-002 | 215 bp | View |
MO961677.1 | emblrelpat | Sequence 18 from patent US 10597429. | 5305 bp | unidentified | QL-ELE-00-002 | 215 bp | View |
LZ186255.1 | emblrelpat | JP 2017141261-A/18: THERAPEUTIC COM... | 8084 bp | synthetic construct | QL-ELE-00-002 | 215 bp | View |
LZ186256.1 | emblrelpat | JP 2017141261-A/19: THERAPEUTIC COM... | 8122 bp | synthetic construct | QL-ELE-00-002 | 215 bp | View |
LZ186258.1 | emblrelpat | JP 2017141261-A/21: THERAPEUTIC COM... | 8035 bp | synthetic construct | QL-ELE-00-002 | 215 bp | View |
LZ207974.1 | emblrelpat | WO 2017131097-A/1: Adamantane deriv... | 6631 bp | synthetic construct | QL-ELE-00-002 | 215 bp | View |
LZ217145.1 | emblrelpat | JP 2017520256-A/1: T7 EXPRESSION SY... | 5990 bp | synthetic construct | QL-ELE-00-002 | 215 bp | View |
LZ217186.1 | emblrelpat | JP 2017520256-A/42: T7 EXPRESSION S... | 9023 bp | synthetic construct | QL-ELE-00-002 | 215 bp | View |
LZ218946.1 | emblrelpat | JP 2017158550-A/17: Therapeutic use... | 6165 bp | synthetic construct | QL-ELE-00-002 | 215 bp | View |
MO962682.1 | emblrelpat | Sequence 371 from patent US 10597648. | 5933 bp | unidentified | QL-ELE-00-002 | 215 bp | View |
MO962689.1 | emblrelpat | Sequence 378 from patent US 10597648. | 8114 bp | unidentified | QL-ELE-00-002 | 215 bp | View |
LZ230690.1 | emblrelpat | JP 2017192342-A/4: Method of produc... | 795 bp | synthetic construct | QL-ELE-00-002 | 215 bp | View |
MO962697.1 | emblrelpat | Sequence 386 from patent US 10597648. | 6854 bp | unidentified | QL-ELE-00-002 | 215 bp | View |
MO962732.1 | emblrelpat | Sequence 451 from patent US 10597648. | 6547 bp | unidentified | QL-ELE-00-002 | 215 bp | View |
MO964035.1 | emblrelpat | Sequence 1805 from patent US 10597648. | 8750 bp | unidentified | QL-ELE-00-002 | 215 bp | View |
MO964042.1 | emblrelpat | Sequence 1812 from patent US 10597648. | 8729 bp | unidentified | QL-ELE-00-002 | 215 bp | View |
Related publications:
Petrillo, M., et al. “JRC GMO-Amplicons: A Collection of Nucleic Acid Sequences Related to Genetically Modified Organisms.” Database (Oxford), vol. 2015 bav101, 30 Sep. 2015, doi:10.1093/database/bav101.
Angers-Loustau, A., et al. “Using the EURL GMFF Online Bioinformatics Resources: A how-to Guide for Practical JRC GMO-Matrix and JRC GMO-Amplicons Case Uses.” European Commission, Ispra, JRC101853, 2016.